The cluster is small in dollar terms but involves multiple C-suite executives selling on the same day, which is atypical for routine diversification. Monitor for any upcoming pipeline data readouts or regulatory updates that could explain the timing.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 3 $10.64entry
- T+1 · 2mo ago 0.00%α +0.39% · $10.64
- T+5 · 2mo ago −1.41%α −0.26% · $10.49
- T+20 · 7w ago −34.59%α −34.38% · $6.96
- T+51 · todayOpen
- T+60 · in 13d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Five senior executives at Ocular Therapeutix, including the Chief Scientific Officer, Chief Operating Officer, and Chief Development Officer, sold a total of ~$333K in shares over a one-week period. While the dollar amount is modest relative to the $2.4B market cap (0.01%), the cluster involves multiple C-suite insiders selling on the same day, which warrants attention despite the academic literature showing cluster sales are less informative than buys. The sales follow a strong recent stock performance and occur ahead of potential pipeline catalysts for the company's lead drug candidate.
Key Financial Metrics
Key Facts
- Five insiders sold shares totaling ~$333K from Aug 24-31, 2026
- Sales include CSO, COO, Chief Development Officer, Chief Strategy Officer, and a senior executive
- All sales were open-market transactions at prices between $10.24-$10.78
- Total sales represent ~0.01% of OCUL's $2.4B market cap
- No insider purchases were reported in the cluster window
Financial Impact
~$333K in insider sales, representing 0.01% of market cap
Risk Factors
- Insider sales may signal management caution ahead of pipeline milestones
- No insider buying to offset the selling cluster
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-OCUL-1788412176966 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Viewing Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers